To test the effect of the pharmacological inhibition of P2X7 receptors, we utilized BBG, a P2X7 receptor antagonist that penetrates the blood brain barrier, and is efficacious in animal models of spinal cord injury [17,18] as well as Huntington's disease [20] in the dose applied. This evidence concerns the gene P2RX7 and juvenile Huntington disease.